SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 58.19+0.3%11:52 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (323)6/10/2010 11:34:37 AM
From: david nordic1 Recommendation  Read Replies (2) of 507
 
"""The best cancer drug in 25 years per the lead cancer investigator.""" Sorry, I was going from memory and here is the exact quote:

Ignace Vergote, Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, European Union and Lead Investigator of the NKTR-102 study said, "NKTR-102 is one of the most promising agents for platinum-resistant ovarian cancer I have seen in 25 years, as evidenced by the number of women in the study with tumor response and rapid biochemical response. This drug warrants further definitive Phase 3 testing as quickly as possible."

Of course Nektar is seeking approval based on Phase IIB results. I think NKTR 102 will be approved early next year.
Unmet needs.


The Breast Cancer Phase II preliminary data matches Ovarian Cancer effectiveness. I point you to the Phase IIB results.
The bottom line is the data. Talk is cheap. What do you think about the data?

It seems you have a problem with Robin??? Robin cut a NKTR 118/119 pain market deal with AZN for 1.5B retaining 1/3, NKTR 061 inhaled amikacin deal with Bayer for 1/3. NKTR is seeking a partner for NKTR 102 retaining north of 1/3. Robin is straight forward, square shooter and deliveries what he says he will do. He makes a point of keeping his word. As a CEO, I like him. Amgen Neulasta deal is next up.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News